{
    "root": "0043f6db-decd-4d53-a301-35f2f7a63664",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CIBINQO",
    "value": "20250320",
    "ingredients": [
        {
            "name": "ABROCITINIB",
            "code": "73SM5SF3OR"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A",
            "code": "H8AV0SQX4D"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.",
    "contraindications": "• For recommended testing, evaluations, and procedures prior to CIBINQO initiation, see Full Prescribing Information. ( 2.1 ) • Recommended dosage is 100 mg orally once daily. ( 2.2 ) • 200 mg orally once daily is recommended for those patients who are not responding to 100 mg once daily. ( 2.2 ) • Moderate renal impairment: 50 mg once daily or 100 mg once daily for those patients who are not responding to 50 mg once daily. ( 2.3 ) • CYP2C19 poor metabolizer: 50 mg once daily or 100 mg once daily for those patients who are not responding to 50 mg once daily. ( 2.4 ) • For dosage modifications for certain adverse reactions, see Full Prescribing Information. ( 2.6 )",
    "warningsAndPrecautions": "CIBINQO is supplied as: \n                  \n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Dosage Form\n                              \n                           \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 Description\n                              \n                           \n                           \n                              \n                                 Bottle Size\n                                 \n                                 (number of tablets)\n                              \n                           \n                           \n                              \n                                 NDC Number\n                              \n                           \n                        \n                        \n                           \n                              Tablets\n                           \n                           \n                              50 mg\n                           \n                           \n                              Pink, oval tablet debossed with \"PFE\" on one side and \"ABR 50\" on the other.\n                           \n                           \n                              30 count bottle\n                           \n                           \n                              0069-0235-30\n                           \n                        \n                        \n                           \n                              Tablets\n                           \n                           \n                              100 mg\n                           \n                           \n                              Pink, round tablet debossed with \"PFE\" on one side and \"ABR 100\" on the other.\n                           \n                           \n                              30 count bottle\n                           \n                           \n                              0069-0335-30\n                           \n                        \n                        \n                           \n                              Tablets\n                           \n                           \n                              200 mg\n                           \n                           \n                              Pink, oval tablet debossed with \"PFE\" on one side and \"ABR 200\" on the other.\n                           \n                           \n                              30 count bottle\n                           \n                           \n                              0069-0435-30",
    "adverseReactions": "CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment [see Warnings and Precautions (5.6), Drug Interactions (7.2), and Clinical Pharmacology (12.2)]."
}